AU751433B2 - Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method - Google Patents

Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method Download PDF

Info

Publication number: AU751433B2
Authority: AU; Australia
Prior art keywords: helicobacter; route; immunogenic agent; use according; administered
Prior art date: 1997-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU72768/98A

Other languages

English (en)

Other versions

AU7276898A (en

Inventor

Bruno Guy

Jean Haensler

Cynthia K. Lee

Thomas P. Monath

Richard A Weltzin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MERIEUX ORAVAX

Original Assignee

MERIEUX ORAVAX

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-30

Filing date

1998-04-30

Publication date

2002-08-15

1997-04-30 Priority claimed from FR9705609A external-priority patent/FR2762788B1/fr

1998-04-30 Application filed by MERIEUX ORAVAX filed Critical MERIEUX ORAVAX

1998-11-24 Publication of AU7276898A publication Critical patent/AU7276898A/en

2002-08-15 Application granted granted Critical

2002-08-15 Publication of AU751433B2 publication Critical patent/AU751433B2/en

2018-04-30 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

241000589989 Helicobacter Species 0.000 title claims description 102
238000000034 method Methods 0.000 title claims description 82
230000009885 systemic effect Effects 0.000 title claims description 35
239000000203 mixture Substances 0.000 title claims description 17
238000002649 immunization Methods 0.000 title description 39
230000003053 immunization Effects 0.000 title description 38
229960005486 vaccine Drugs 0.000 title description 17
108090000765 processed proteins & peptides Proteins 0.000 claims description 109
108010046334 Urease Proteins 0.000 claims description 101
239000003795 chemical substances by application Substances 0.000 claims description 70
241000699670 Mus sp. Species 0.000 claims description 66
102000004196 processed proteins & peptides Human genes 0.000 claims description 64
230000002163 immunogen Effects 0.000 claims description 63
229920001184 polypeptide Polymers 0.000 claims description 61
239000002671 adjuvant Substances 0.000 claims description 44
230000028993 immune response Effects 0.000 claims description 39
239000013598 vector Substances 0.000 claims description 38
108020004414 DNA Proteins 0.000 claims description 32
238000002360 preparation method Methods 0.000 claims description 31
102000053602 DNA Human genes 0.000 claims description 27
239000008194 pharmaceutical composition Substances 0.000 claims description 27
238000002965 ELISA Methods 0.000 claims description 25
238000007920 subcutaneous administration Methods 0.000 claims description 25
241000124008 Mammalia Species 0.000 claims description 24
238000007918 intramuscular administration Methods 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 23
241000894006 Bacteria Species 0.000 claims description 22
HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims description 20
230000006698 induction Effects 0.000 claims description 20
239000002502 liposome Substances 0.000 claims description 19
108010049048 Cholera Toxin Proteins 0.000 claims description 18
102000009016 Cholera Toxin Human genes 0.000 claims description 18
241000894007 species Species 0.000 claims description 17
150000002632 lipids Chemical class 0.000 claims description 16
206010019375 Helicobacter infections Diseases 0.000 claims description 15
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
229940037003 alum Drugs 0.000 claims description 14
230000001737 promoting effect Effects 0.000 claims description 13
239000004202 carbamide Substances 0.000 claims description 11
239000013592 cell lysate Substances 0.000 claims description 11
239000003053 toxin Substances 0.000 claims description 10
231100000765 toxin Toxicity 0.000 claims description 10
241000588724 Escherichia coli Species 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
238000007911 parenteral administration Methods 0.000 claims description 7
239000004005 microsphere Substances 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 5
101710146739 Enterotoxin Proteins 0.000 claims description 4
241000288906 Primates Species 0.000 claims description 4
239000000147 enterotoxin Substances 0.000 claims description 4
231100000655 enterotoxin Toxicity 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 4
241000193163 Clostridioides difficile Species 0.000 claims description 3
108010028921 Lipopeptides Proteins 0.000 claims description 3
108010081690 Pertussis Toxin Proteins 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
241000590002 Helicobacter pylori Species 0.000 claims 4
229940037467 helicobacter pylori Drugs 0.000 claims 4
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 claims 1
230000004044 response Effects 0.000 description 43
241000282693 Cercopithecidae Species 0.000 description 39
239000000427 antigen Substances 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
230000001580 bacterial effect Effects 0.000 description 24
230000000694 effects Effects 0.000 description 24
238000002474 experimental method Methods 0.000 description 22
238000012360 testing method Methods 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 18
210000002784 stomach Anatomy 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
101150026046 iga gene Proteins 0.000 description 14
230000002496 gastric effect Effects 0.000 description 13
230000001681 protective effect Effects 0.000 description 13
210000004705 lumbosacral region Anatomy 0.000 description 11
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
208000007882 Gastritis Diseases 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
230000037452 priming Effects 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
238000001574 biopsy Methods 0.000 description 7
239000000872 buffer Substances 0.000 description 7
238000009472 formulation Methods 0.000 description 7
210000004400 mucous membrane Anatomy 0.000 description 7
239000013642 negative control Substances 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
108700012359 toxins Proteins 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
108010006591 Apoenzymes Proteins 0.000 description 6
241000282560 Macaca mulatta Species 0.000 description 6
229930006000 Sucrose Natural products 0.000 description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
244000005700 microbiome Species 0.000 description 6
230000000069 prophylactic effect Effects 0.000 description 6
239000005720 sucrose Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
125000002091 cationic group Chemical group 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
230000035772 mutation Effects 0.000 description 5
239000013641 positive control Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 4
PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000006166 lysate Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
241000590017 Helicobacter felis Species 0.000 description 3
208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
-1 another molecule Substances 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
230000001332 colony forming effect Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
101150028842 ctxA gene Proteins 0.000 description 3
238000012258 culturing Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
229940035032 monophosphoryl lipid a Drugs 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
210000003079 salivary gland Anatomy 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
241000272478 Aquila Species 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
102000016938 Catalase Human genes 0.000 description 2
108010053835 Catalase Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
241001495142 Helicobacter heilmannii Species 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
241001644525 Nastus productus Species 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
241000607762 Shigella flexneri Species 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
210000004241 Th2 cell Anatomy 0.000 description 2
241000607626 Vibrio cholerae Species 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000003304 gavage Methods 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000007388 punch biopsy Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229940063673 spermidine Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
229940118696 vibrio cholerae Drugs 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 1
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
RYOFERRMXDATKG-YEUCEMRASA-N 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC RYOFERRMXDATKG-YEUCEMRASA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000004300 Atrophic Gastritis Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000178270 Canarypox virus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
241000272184 Falconiformes Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
208000036495 Gastritis atrophic Diseases 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
241000590006 Helicobacter mustelae Species 0.000 description 1
101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
206010054949 Metaplasia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001092142 Molina Species 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
108700024476 N-acetylmuramyl-alanylglutamine methyl ester Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
101150090155 R gene Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101150019179 SAF1 gene Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000194026 Streptococcus gordonii Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
101100286925 Zea mays IN2-1 gene Proteins 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000004075 alteration Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229960003150 bupivacaine Drugs 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000016644 chronic atrophic gastritis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000023652 chronic gastritis Diseases 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
239000007382 columbia agar Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002185 fusiogenic effect Effects 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
229950009774 gramicidin s Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000050459 human LTF Human genes 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
101150027374 irgA gene Proteins 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
229950005634 loxoribine Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000015689 metaplastic ossification Effects 0.000 description 1
OXSVRXKURHXDIV-OTVXWGLQSA-N methyl (2r)-2-[[(2s)-2-[2-[(2s,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound NC(=O)CC[C@H](C(=O)OC)NC(=O)[C@H](C)NC(=O)C(C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O OXSVRXKURHXDIV-OTVXWGLQSA-N 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical class NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
108700026215 vpr Genes Proteins 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AU72768/98A 1997-04-30 1998-04-30 Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method Ceased AU751433B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
FR9705609		1997-04-30
FR9705609A FR2762788B1 (fr)	1997-04-30	1997-04-30	Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
FR9715731		1997-12-08
FR9715731		1997-12-08
PCT/US1998/008890 WO1998048835A1 (fr)	1997-04-30	1998-04-30	Vaccin anti-helicobacter administrable par voie generale sous-diaphragmatique, et procede combine d'immunisation par les muqueuses/parenterale

Publications (2)

Publication Number	Publication Date
AU7276898A AU7276898A (en)	1998-11-24
AU751433B2 true AU751433B2 (en)	2002-08-15

Family

ID=26233514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU72768/98A Ceased AU751433B2 (en)	1997-04-30	1998-04-30	Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method

Country Status (10)

Country	Link
EP (1)	EP1017417A1 (fr)
JP (1)	JP2002512619A (fr)
KR (1)	KR20010020366A (fr)
CN (1)	CN1254292A (fr)
AU (1)	AU751433B2 (fr)
BR (1)	BR9809426A (fr)
CA (1)	CA2289253A1 (fr)
HU (1)	HUP0003388A3 (fr)
NO (1)	NO995290L (fr)
WO (1)	WO1998048835A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0029919D0 (en) *	2000-12-07	2001-01-24	Chiron Spa	Helicobacter pylori prime & boost vaccination
ES2569907T3 (es)	2008-06-27	2016-05-13	Zoetis Services Llc	Composiciones adyuvantes novedosas
UA130246C2 (uk)	2013-09-19	2025-12-31	Зоетіс Сервісіз Ллс	Ад'ювант на основі олії
CN115317600A (zh)	2015-01-16	2022-11-11	硕腾服务有限责任公司	口蹄疫疫苗
CN108743929B (zh) *	2018-06-14	2021-07-27	四川大学	一种用作尿素清除剂的脲酶凝胶微球的制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993018150A1 (fr) *	1992-03-02	1993-09-16	Biocine S.P.A.	Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics
WO1995033482A1 (fr) *	1994-06-08	1995-12-14	Csl Limited	Traitement et prevention d'infections causees par les bacteries du genre helicobacter
WO1996038475A1 (fr) *	1995-06-01	1996-12-05	Astra Aktiebolag	Antigenes d'helicobacter pylori et compositions de vaccins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5679769A (en) *	1994-03-15	1997-10-21	Sloan-Kettering Institute For Cancer Research	Synthesis of asparagine-linked glycopeptides on a polymeric solid support
US5610060A (en) *	1994-06-24	1997-03-11	The United States Of America As Represented By The Department Of Health And Human Services	Isolated Helicobacter hepaticus
SK165197A3 (en) *	1995-06-07	1999-01-11	Astra Ab	Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics

1998
- 1998-04-30 CA CA002289253A patent/CA2289253A1/fr not_active Abandoned
- 1998-04-30 KR KR1019997009988A patent/KR20010020366A/ko not_active Ceased
- 1998-04-30 EP EP98920126A patent/EP1017417A1/fr not_active Withdrawn
- 1998-04-30 AU AU72768/98A patent/AU751433B2/en not_active Ceased
- 1998-04-30 HU HU0003388A patent/HUP0003388A3/hu unknown
- 1998-04-30 CN CN98804722A patent/CN1254292A/zh active Pending
- 1998-04-30 JP JP54744198A patent/JP2002512619A/ja active Pending
- 1998-04-30 WO PCT/US1998/008890 patent/WO1998048835A1/fr not_active Ceased
- 1998-04-30 BR BR9809426-2A patent/BR9809426A/pt not_active Application Discontinuation
1999
- 1999-10-29 NO NO995290A patent/NO995290L/no not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993018150A1 (fr) *	1992-03-02	1993-09-16	Biocine S.P.A.	Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics
WO1995033482A1 (fr) *	1994-06-08	1995-12-14	Csl Limited	Traitement et prevention d'infections causees par les bacteries du genre helicobacter
WO1996038475A1 (fr) *	1995-06-01	1996-12-05	Astra Aktiebolag	Antigenes d'helicobacter pylori et compositions de vaccins

Also Published As

Publication number	Publication date
CA2289253A1 (fr)	1998-11-05
NO995290L (no)	1999-12-29
KR20010020366A (ko)	2001-03-15
HUP0003388A3 (en)	2001-06-28
HUP0003388A2 (hu)	2001-02-28
CN1254292A (zh)	2000-05-24
EP1017417A1 (fr)	2000-07-12
WO1998048835A1 (fr)	1998-11-05
JP2002512619A (ja)	2002-04-23
AU7276898A (en)	1998-11-24
NO995290D0 (no)	1999-10-29
BR9809426A (pt)	2000-06-13

Legal Events

Date	Code	Title	Description
2002-12-12	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
Corthésy-Theulaz et al.	1995	Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice
EP0771214B1 (fr)	2004-10-20	Traitement et prevention d'infections causees par les bacteries du genre helicobacter
JP5745731B2 (ja)	2015-07-08	サルモネラワクチン
EP1229928A2 (fr)	2002-08-14	Utilisation de vecteurs de salmonella a des fins de vaccination contre l'infection par helicobacter
AU750379B2 (en)	2002-07-18	Anti-helicobacter vaccine composition comprising a Th1 adjuvant
US6762295B2 (en)	2004-07-13	Protective helicobacter antigens
JPH11509200A (ja)	1999-08-17	粘膜アジュバントとしてのクロストリジウム・ディフィシール（ＣｌｏｓｔｒｉｄｉｕｍＤｉｆｆｉｃｉｌｅ）トキシン
AU751433B2 (en)	2002-08-15	Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
US9119803B2 (en)	2015-09-01	Carious tooth vaccine and preparation method
US20040033240A1 (en)	2004-02-19	Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
WO1995027508A1 (fr)	1995-10-19	Composition utilisable pour induire une reponse immunitaire
Medaglini et al.	1997	Recombinant Gram-positive bacteria as vehicles of vaccine antigens
MXPA99009915A (es)	2000-07-01	Composicion de vacuna anti-helicobacter para usomediante la ruta sistematica sub-diafragmatica, ymetodo de inmunizacion mucosal/parenteral combinado
CZ361799A3 (cs)	2000-07-12	Použití imunogenní látky odvozené od bakterie rodu Helicobacter a způsob prevence nebo léčby infekcí způsobených těmito bakteriemi
JPH11240844A (ja)	1999-09-07	肺炎球菌抗原の経口投与
JP2009078995A (ja)	2009-04-16	歯周病用免疫ワクチン
FR2762788A1 (fr)	1998-11-06	Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
AU702878B2 (en)	1999-03-11	Treatment and prevention of helicobacter infection
JP2023516397A (ja)	2023-04-19	タンパク質抗原を発現するように操作される生チフス菌ベクターおよびその使用方法
Kotloff et al.	2004	Vaccine Strategies Against Helicobacter Pylori
FR2762787A1 (fr)	1998-11-06	Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
AU2249900A (en)	2000-06-08	Composition for inducing a mucosal immune response
WO1998049318A1 (fr)	1998-11-05	Composition vaccinale anti-helicobacter a base d'adn